Cyclo Therapeutics Inc (CYTH)

[octagramt]

thanks. At this point my thought is that CTD needs to post profitable cash flow based on revenue instead of Adjustments to Net Income, which was $301,258, while cash flow from actual operating activities was a loss, ($193,127). Revenue did grow to $623,874 but expenses grew to $824,809 (when the investment income of $7,808 is included the net loss before taxes is reduced to $193,127 from $200,935). I am excited to see what will happen to the stock after the company is able to have a profitable quarter based on revenue. Institutions should have an easier time getting into this stock at that point. Best of a worst case scenario though is that the company would continue to have profitable quarters, the stock not go up due to lack of institutional involvement, but the company use that money to eventually pay some sort of one time dividend or offer an attractive stock buyback. All of this would take time of course, but as long as CTD's fundamentals remain intact, there is reason to hold on the the stock. I am giving this a minimum of two years as the plant should be finished by the end of the year and then I would like to see a full year's results of having the plant, which should reduce costs, and any of the benefits that the orphan drug designation contributed to the company.